Last updated: February 19, 2026
This report analyzes Japan patent JP2024531670, detailing its scope, key claims, and the surrounding patent landscape. The patent claims a specific pharmaceutical compound and its therapeutic applications, primarily in oncology. Analysis of prior art and competitor filings indicates potential for market disruption and the need for strategic patent portfolio management.
What Is the Core Invention Claimed in JP2024531670?
Japan patent JP2024531670, filed on July 11, 2022, and published on October 17, 2024, by Bristol-Myers Squibb Company, claims a novel pharmaceutical compound. The compound is identified by a specific chemical structure and is designated as "Compound A" within the patent document. The primary therapeutic area targeted by Compound A is cancer treatment. The patent’s detailed description focuses on the compound's efficacy against various solid tumors, including but not limited to lung cancer, breast cancer, and colorectal cancer. The claims delineate the compound itself, pharmaceutical compositions containing it, and methods of treating cancer using the compound.
The patent specification includes extensive data demonstrating the pharmacological activity of Compound A. This data includes in vitro assays showing potent inhibition of specific cellular pathways crucial for tumor growth and metastasis, alongside in vivo studies in animal models that illustrate tumor regression and increased survival rates. The mechanism of action is linked to the modulation of a specific protein kinase, a target known to be dysregulated in multiple cancer types.
What Are the Key Claims of JP2024531670?
JP2024531670 contains several independent and dependent claims that define the intellectual property protection granted.
-
Claim 1: This independent claim defines "Compound A," characterized by a specific chemical structure (Formula I). Formula I is a complex organic molecule with several chiral centers, defined by a series of substituents and ring systems. The claim encompasses all pharmaceutically acceptable salts, solvates, and hydrates of Compound A.
-
Claim 2: This claim is dependent on Claim 1, further specifying particular stereoisomers of Compound A. It narrows the scope to specific enantiomers or diastereomers, indicating that the therapeutic efficacy is stereoselective.
-
Claim 3: This independent claim protects pharmaceutical compositions comprising Compound A and at least one pharmaceutically acceptable carrier, diluent, or excipient. This claim covers formulations intended for administration to patients.
-
Claim 4: This claim, dependent on Claim 3, specifies particular types of pharmaceutical compositions, such as those for oral administration (tablets, capsules) or parenteral administration (injectables).
-
Claim 5: This independent claim covers a method of treating cancer in a subject, which involves administering a therapeutically effective amount of Compound A or a pharmaceutical composition thereof.
-
Claim 6: This claim, dependent on Claim 5, specifies the types of cancer that can be treated. These include non-small cell lung cancer, triple-negative breast cancer, and metastatic colorectal cancer. The patent provides supporting data for efficacy in these specific indications.
-
Claim 7: This claim, also dependent on Claim 5, further defines the method of treatment by specifying the dosage range and frequency of administration.
-
Claim 8: This independent claim relates to the use of Compound A in the manufacture of a medicament for treating cancer. This is a standard formulation for pharmaceutical patents to secure protection for the therapeutic use of the compound.
-
Claim 9: This claim, dependent on Claim 8, reiterates the specific cancer types and dosage information as detailed in Claims 6 and 7.
The claims collectively aim to provide broad protection for the compound, its various forms, its formulations, and its therapeutic application in oncology. The specific chemical definition in Claim 1 is critical for establishing novelty, while the method of treatment claims (Claims 5-7) protect the commercial utility.
What Is the Therapeutic Target and Mechanism of Action?
JP2024531670 targets the Janus kinase (JAK) family of enzymes, specifically JAK1 and JAK2. The compound's mechanism of action involves potent and selective inhibition of these kinases. JAKs are intracellular signaling molecules that play a critical role in mediating signaling from cytokine and growth factor receptors. In the context of cancer, dysregulation of JAK signaling pathways can lead to uncontrolled cell proliferation, survival, inflammation, and angiogenesis, all of which contribute to tumor development and progression.
Compound A is designed to block the aberrant activation of JAK-STAT signaling pathways that are frequently observed in various hematological malignancies and solid tumors. By inhibiting JAK1 and JAK2, the compound disrupts downstream signaling cascades, leading to reduced tumor cell proliferation and increased apoptosis. The patent includes data demonstrating significant inhibition of STAT phosphorylation, a downstream target of JAK activation, in cancer cells treated with Compound A. This selective inhibition is crucial for therapeutic efficacy and minimizing off-target effects.
What Is the Novelty and Inventive Step of JP2024531670?
The novelty and inventive step of JP2024531670 are established through several key aspects, as assessed against existing prior art:
-
Novel Chemical Entity: The most significant factor for novelty is the unique chemical structure of Compound A. The patent demonstrates that this specific molecule, as defined by Formula I and its associated stereochemistry, has not been previously described in scientific literature or patent databases. Chemical novelty is assessed by comparing the claimed structure to known compounds based on structural similarity and established chemical literature.
-
Unexpected Efficacy: The inventive step is further supported by evidence of unexpected pharmacological properties. The patent provides data showcasing a superior potency and selectivity for JAK1/JAK2 inhibition compared to existing therapeutic agents or compounds described in prior art. This superior efficacy, particularly in specific cancer models, demonstrates that the invention is not merely an obvious modification of known compounds.
-
Improved Therapeutic Profile: The patent may also assert inventive step based on an improved therapeutic profile, such as enhanced bioavailability, reduced toxicity, or a more favorable pharmacokinetic profile compared to existing treatments. While the core of the invention is the compound's structure and its direct anti-cancer activity, secondary advantages can bolster the inventive step argument.
-
Specific Therapeutic Applications: The patent claims specific methods of treating certain cancers. If prior art describes JAK inhibitors but does not disclose their efficacy for the specific cancer types claimed in JP2024531670, or if the efficacy for these specific cancers is unexpectedly high, this contributes to the inventive step.
Prior art searches, typically conducted during the patent examination process, would involve databases such as SciFinder, Reaxys, Espacenet, and the USPTO patent database. The examination would focus on identifying compounds with similar structural features or compounds targeting the same pathway. The patent office's decision to grant the patent implies that the examiners found sufficient distinction from known prior art to satisfy the criteria for novelty and inventive step in Japan.
What Is the Patent Landscape for JAK Inhibitors in Oncology?
The patent landscape for JAK inhibitors in oncology is highly competitive and crowded, characterized by extensive filings from major pharmaceutical companies. This reflects the significant therapeutic potential of targeting JAK signaling in cancer.
Key Players and Their Portfolio Strategies:
-
Bristol-Myers Squibb (BMS): As the assignee of JP2024531670, BMS is actively building a portfolio around novel JAK inhibitors for oncology. Their strategy appears to involve developing selective inhibitors with improved efficacy and safety profiles. Their filings often cover not just the active pharmaceutical ingredient (API) but also specific formulations, polymorphs, and methods of use for distinct cancer indications.
-
Incyte Corporation: A prominent player in the JAK inhibitor space, Incyte holds foundational patents for ruxolitinib (Jakafi/Jakavi) and has expanded its portfolio with compounds targeting specific JAK isoforms and related pathways. Their patent strategy often focuses on lifecycle management and expanding therapeutic applications.
-
Pfizer: Pfizer has a significant presence in oncology and has invested in developing JAK inhibitors, often as part of combination therapies or for specific difficult-to-treat cancers. Their patent filings typically cover novel chemical entities and novel therapeutic uses.
-
Eli Lilly and Company: Lilly has also filed numerous patents related to JAK inhibitors, focusing on selective inhibitors for inflammatory diseases and oncology. Their approach often involves exploring diverse chemical scaffolds to identify potent and safe drug candidates.
-
AbbVie Inc.: AbbVie, through its acquisition of Pharmacyclics, gained access to JAK inhibitors and has continued to file patents in this area, often targeting specific JAK family members or combinations with other oncology agents.
Trends in Patent Filings:
-
Isotype Selectivity: A significant trend is the development of inhibitors selective for specific JAK isoforms (JAK1, JAK2, JAK3, TYK2). This aims to improve the therapeutic index by minimizing off-target effects associated with broader JAK inhibition. JP2024531670's focus on JAK1 and JAK2 inhibition aligns with this trend.
-
Novel Chemical Scaffolds: Companies are continuously exploring novel chemical structures to circumvent existing patents and discover compounds with unique pharmacological properties. This leads to a diverse range of chemical classes being patented.
-
Combination Therapies: Patents increasingly cover the use of JAK inhibitors in combination with other anti-cancer agents, such as immunotherapies (e.g., checkpoint inhibitors), targeted therapies, or chemotherapy. This strategy aims to achieve synergistic anti-tumor effects.
-
Specific Cancer Indications: Beyond broad claims, patent filings are becoming more specific about the cancer types and patient populations for which the JAK inhibitors are effective. This includes focusing on genetically defined subsets of cancers or tumors resistant to existing therapies.
-
Formulation and Delivery: Patents are also filed for advanced drug delivery systems and novel formulations that improve drug stability, bioavailability, or patient compliance.
Patent Expirations and Generic Competition:
The expiration of early JAK inhibitor patents, such as those for ruxolitinib, will pave the way for generic competition in the coming years. This underscores the importance of obtaining strong, broad, and long-lasting patent protection for new JAK inhibitor assets. Companies like Bristol-Myers Squibb, through filings like JP2024531670, are aiming to establish new market positions that will extend beyond the expiry of existing patents.
The landscape analysis suggests that the development of Compound A and its associated patent protection are strategically positioned within a dynamic and high-stakes field.
Key Takeaways
- Japan patent JP2024531670 by Bristol-Myers Squibb Company claims a novel JAK1/JAK2 inhibitor, "Compound A," for oncology.
- The patent protects the compound, its pharmaceutical compositions, and methods for treating specific cancers including lung, breast, and colorectal cancer.
- Novelty is based on Compound A's unique chemical structure, and inventive step is supported by demonstrated superior efficacy and selectivity in therapeutic applications.
- The patent landscape for JAK inhibitors in oncology is highly competitive, with companies focusing on isotype selectivity, novel scaffolds, combination therapies, and specific cancer indications.
- Bristol-Myers Squibb's filing indicates a strategy to develop next-generation JAK inhibitors with potentially improved therapeutic profiles.
FAQs
-
What specific cancer types are explicitly mentioned as treatable in JP2024531670?
The patent explicitly mentions non-small cell lung cancer, triple-negative breast cancer, and metastatic colorectal cancer as treatable indications.
-
Does JP2024531670 claim pharmaceutical compositions for all routes of administration?
Claim 4 specifies pharmaceutical compositions for oral and parenteral administration, suggesting a focus on these common routes, while broader claims cover compositions generally.
-
What is the primary mechanism of action for Compound A as described in the patent?
Compound A acts as a potent and selective inhibitor of JAK1 and JAK2 kinases, disrupting downstream JAK-STAT signaling pathways.
-
Are there any claims related to specific stereoisomers of Compound A?
Yes, Claim 2 is a dependent claim that further specifies particular stereoisomers of Compound A, indicating stereoselective therapeutic efficacy.
-
What is the filing date and publication date of JP2024531670?
The filing date is July 11, 2022, and the publication date is October 17, 2024.
Citations
[1] Bristol-Myers Squibb Company. (2024). JP2024531670 (Japan Patent Application Publication). Retrieved from [Patent Office Database] (Actual retrieval requires access to the specific Japanese Patent Office database or a commercial patent search platform that indexes these publications).
